Proactive Investors - Run By Investors For Investors

GSK warns 2018 earnings hinge on generic competition to its blockbuster Advair inhaler

If a generic competitor comes to market this summer as expected, GSK said earnings will fall by between 0-3%, while if a competitor isn’t forthcoming, earnings will rise by 4-7%
man using inhaler
Advair made more than £1.6bn in sales last year, but that could halve in 2018.

Increased competition in its core HIV and respiratory businesses could hit GlaxoSmithKline PLC’s (LON:GSK) earnings in 2018, the UK pharma giant warned on Wednesday.

At constant exchange rates, adjusted earnings per share grew 4% in 2017 to 111.8p, but GSK sees them flat to down 3% in 2018 if generic versions of its blockbuster Advair asthma treatment launch later in the year as expected.

READ: Barclays cites progress in HIV and new shingles vaccine as it turns bullish on GSK

US Advair sales could halve​

In the US, Advair generated sales of £1.6bn in 2017, but should competition from generics materialise, GSK reckons sales in the States will dive to around £750mln.

If a generic substitute doesn’t come on the market, the FTSE 100 drugmaker expects 2018 earnings to be rise by between 4-7%.

Despite the Advair uncertainty and looming competition from Gilead Sciences Inc’s (NASDAQ:GILD) rival HIV treatment, chief executive Emma Walmsley said she was “increasingly confident” her company could continue to deliver mid-to-high single digit earnings growth over the next few years.

Overall, the UK’s largest pharma outfit topped expectations with its fourth quarter results.

£1.7bn one-off tax hit​

GSK reported a fourth-quarter adjusted EPS of 27.2p, on sales of £7.64bn. According to Thomson Reuters, Wall Street had been expecting 26.0p and £7.49bn.

The London-based firm added it had taken a one-off tax charge of £1.7bn in its 2017 earnings as a result of the recently-introduced tax reforms in the US.

Going forward though, Glaxo expects the changes to lower its effective tax rate on underlying profits by two to three basis points.

The company declared a 23p dividend, amounting to a full-year pay-out of 80p, and backed its divi guidance, saying it continued to expect to pay out 80p again in 2018.

GSK shares edged 0.9% higher to £12.54 on Wednesday afternoon.

View full GSK profile View Profile

GlaxoSmithKline PLC Timeline

Related Articles

test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
eye
November 19 2018
“It’s a blended model of highly cash generative assets and top line growth”
car-t cells definition
September 24 2018
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use